Edesa Biotech (EDSA) vs INmune Bio (INMB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Edesa Biotech (EDSA) has outperformed INmune Bio (INMB) over the past year, gaining 34.6% versus a loss of 9.0%. Over five years, INMB leads with a -90.2% price change compared with -93.3% for EDSA. INmune Bio is the larger company by market cap ($50.8 million vs $49.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDSA | INMB |
|---|---|---|
| Share price | $3.66 | $1.83 |
| Market cap | $49.45M | $50.79M |
| 1-day change | -5.79% | -1.61% |
| YTD return | +157.75% | +17.31% |
| 1-year return | +34.56% | -8.96% |
| 5-year return | -93.31% | -90.17% |
| EPS (TTM) | $-1.72 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.32 | $2.60 |
| 52-week low | $0.72 | $1.09 |
| Distance from 52-week high | -81.99% | -29.62% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +346.17% | +282.51% |
| Average volume | 61.89K | 402.12K |
| Shares outstanding | 13.51M | 27.75M |
| Employees | 17 | 21 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDSA has outperformed INMB by 43.5 percentage points over the past year.
About Edesa Biotech
EDSA stock →Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
Healthcare · Biotechnology · 17 employees
About INmune Bio
INMB stock →INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Healthcare · Biotechnology · 21 employees
EDSA vs INMB FAQ
Which is bigger, Edesa Biotech or INmune Bio?
INmune Bio (INMB) is larger, with a market capitalization of $50.79M compared with $49.45M for Edesa Biotech (EDSA).
Which stock has performed better over the past year, EDSA or INMB?
EDSA returned +34.56% over the past 12 months, compared with -8.96% for INMB (price return, excluding dividends). Past performance does not predict future results.
Are Edesa Biotech and INmune Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.